Spectral Medical Inc (TSE:EDT) was downgraded by equities research analysts at Mackie from a “speculative buy” rating to a “sell” rating in a report issued on Monday.

Other equities research analysts have also recently issued research reports about the company. Cormark cut Spectral Medical from a “buy” rating to a “reduce” rating in a report on Monday. GMP Securities reissued a “speculative buy” rating on shares of Spectral Medical in a report on Wednesday, September 14th.

Shares of Spectral Medical (TSE:EDT) opened at 0.235 on Monday. The stock’s 50 day moving average price is $1.24 and its 200 day moving average price is $1.02. The firm’s market cap is $48.58 million. Spectral Medical has a 12-month low of $0.18 and a 12-month high of $2.07.

Spectral Medical Company Profile

Spectral Medical Inc, formerly Spectral Diagnostics Inc, is a therapeutic development company. The Company is focused on the development and commercialization of a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) and the Toraymyxin (PMX) therapeutic. The Company also manufactures and sells certain reagents.

Receive News & Ratings for Spectral Medical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical Inc and related companies with MarketBeat.com's FREE daily email newsletter.